ICON Public Limited (NASDAQ:ICLR) Receives $289.10 Consensus PT from Analysts

ICON Public Limited (NASDAQ:ICLR) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $289.18.

Several brokerages recently weighed in on ICLR. Evercore ISI dropped their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. JPMorgan Chase & Co. cut their price objective on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Truist Financial restated a “buy” rating and set a $284.00 price target (down previously from $295.00) on shares of ICON Public in a research note on Wednesday, December 18th. Finally, StockNews.com downgraded shares of ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th.

Institutional Trading of ICON Public

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Icon Wealth Advisors LLC grew its stake in shares of ICON Public by 861.1% during the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares during the period. Foyston Gordon & Payne Inc acquired a new stake in ICON Public during the third quarter valued at $11,672,000. Kornitzer Capital Management Inc. KS increased its holdings in ICON Public by 15.9% in the second quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock valued at $30,016,000 after buying an additional 13,163 shares in the last quarter. Sara Bay Financial acquired a new position in shares of ICON Public in the third quarter worth about $1,143,000. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in shares of ICON Public during the 2nd quarter worth about $54,000. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Stock Performance

ICLR stock opened at $215.51 on Thursday. ICON Public has a one year low of $183.38 and a one year high of $347.72. The firm has a market cap of $17.78 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 1.54 and a beta of 1.20. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The firm has a 50-day simple moving average of $211.79 and a two-hundred day simple moving average of $274.18.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the previous year, the company earned $3.10 EPS. The company’s revenue was down 1.2% on a year-over-year basis. On average, equities analysts forecast that ICON Public will post 13.42 EPS for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.